
FAQ: What Is The Role of FcRn in Sjogren's Pathogenesis?
In this FAQ video module, Robert Laugherty, explains the role of the neonatal Fc receptor (FcRn) in autoimmune disease, with a focus on Sjögren’s disease. He reviews how FcRn protects immunoglobulin G (IgG) antibodies from degradation and recycles them into circulation, extending their half-life. The discussion explores how this normal immune function can also prolong the presence of pathogenic autoantibodies that contribute to autoimmune inflammation. This episode examines the rationale for FcRn inhibition and the mechanism of action of nipocalimab, a therapy being investigated for Sjögren’s disease and systemic lupus erythematosus (SLE). Robert explains how blocking FcRn interrupts IgG recycling and lowers circulating IgG levels, including disease-associated autoantibodies. He discusses why researchers are studying this approach to address autoimmune disease activity, including the glandular and systemic manifestations of Sjögren’s disease, while highlighting ongoing clinical research. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and other healthcare professionals, this educational overview connects antibody biology with emerging therapeutic approaches in rheumatology. Learn how FcRn-mediated IgG recycling contributes to the rationale for investigating targeted treatments in autoantibody-associated diseases. For more rheumatology education and clinical resources, explore the RhAPP Content Rheum and RhAPP ACE app.